Clinical Trial Update: A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing PT009 with PT005 for COPD exacerbations over 52 weeks completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT005
• PT009

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-09-26